
What is claimed is:

1. A compound having the formula:



(IA),

or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, wherein

X_1 is CR^1 or N; X_2 is CR^2 or N; X_3 is CR^3 or N; X_4 is CR^4 or N; X_5 is CR^5 or N; with the proviso that X_1, X_2, X_3, X_4, and X_5 are not all N;

Y_6 is CR^6 or N; Y_7 is CR^7 or N; Y_8 is CR^8 or N; Y_9 is CR^9 or N; Y_{10} is CR^{10} or N; with the proviso that Y_6, Y_7, Y_8, Y_9, and Y_{10} are not all N; wherein

R^1, R^2, R^4, R^5, R^6, R^7, R^8 and R^{10} are each independently selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) $-CF_3$, (g) $-CF_2H$, (h) $-CFH_2$, (i) $-OCF_3$, (j) $-OCF_2H$, (k) $-OCFH_2$, (l) $-OCH_3$, (m) –CN, (n) $-N_3$, (o) $-NO_2$, (p) $-NR^{11}R^{11}$, (q) $-NR^{11}C(O)R^{11}$, (r) $-C(O)NR^{11}R^{11}$, (s) $-OR^{11}$, (t) –COH, (u) $-CO(C_1-C_8$ alkyl), (v) $-COR^{11}$, (w) $-NR^{11}(CNR^{11})NR^{11}R^{11}$, (x) $-S(O)_pR^{11}$, (y) $-NR^{11}S(O)_pR^{11}$, (z) $-SR^{11}$, (aa) $-SCF_3$, (bb) $-C(CF_3)H$-NH-$CHR^{11}R^{11}$, (cc) $-COOR^{11}$, (dd) $-(OCH_2CH_2)_tR^{11}$, (ee) $-(OCH_2CH_2)_tOR^{11}$, (ff) $-C_1-C_8$ alkyl, (gg) $-C_2-C_8$ alkenyl, (hh) $-C_2-C_8$ alkynyl, (ii) $-(C_1-C_8$ alkyl)–(3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (jj) $-(C_1-C_8$ alkyl)–(3–14 membered saturated, unsaturated, or aromatic carbocycle), (kk) –haloalkyl, (ll) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (mm) –3–14 membered saturated, unsaturated, or aromatic carbocycle, and (nn) $-CHR^{11}$-NH-(3-14 membered saturated, unsaturated, or aromatic heterocycle containing one of more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur);

wherein each (ff) through (nn) is optionally substituted with one or more R^{12}; alternatively, wherein two substituents selected from R^6, R^7, and R^8 are taken together with the carbon atom to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring


containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; wherein each (a) through (b) is optionally substituted with one or more R^{12};

each R^{11} is independently selected from (a) hydrogen, (b) halogen, (c) –OH, (d) –SH, (e) –(C_1–C_8 alkyl)OH, (f) $-OCF_3$, (g) $-OCF_2H$, (h) $-OCFH_2$, (i) $-OCH_3$, (j) $-OR^{12}$, (k) $-COR^{12}$, (l) –CN, (m) $-NO_2$, (n) $-CONH_2$, (o) $-CONR^{12}R^{12}$, (p) $-COCH_3$, (q) $-S(O)_pCH_3$, (r) $-S(O)_pNR^{12}R^{12}$, (s) $-SR^{12}$, (t) –C(O)OH, (u) $-C(O)OR^{12}$, (v) $-N_3$, (w) $-NH_2$, (x) $-NR^{12}C(O)R^{12}$, (y) –NH(C_1–C_8 alkyl), (z) –N(C_1–C_8 alkyl)$_2$, (aa) –C_1–C_8 alkyl, (bb) –C_2–C_8 alkenyl, (cc) –C_2–C_8 alkynyl, (dd) –haloalkyl, (ee) –(C_1–C_8 alkyl)–(3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (ff) –(C_1–C_8 alkyl)–(3–14 membered saturated, unsaturated, or aromatic carbocycle), (gg) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (hh) –3–14 membered saturated, unsaturated, or aromatic carbocycle, and (ii) $-(C=NH)NR^{12}R^{12}$;

wherein each (y) through (hh) is optionally substituted with one or more R^{12};

alternatively two R^{11} substituents are taken together to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, wherein each (a) through (b) is optionally substituted with one or more R^{12};

R^3 is selected from:



wherein R^{3a}, R^{3b}, R^{3c}, R^{3d}, R^{3e}, R^{3f}, R^{3g}, R^{3h}, R^{3i}, R^{3j}, R^{3k}, and R^{3l} are each independently selected from (a) hydrogen, (b) halogen, (c) –CN, (d) $-N_3$, (e) $-NO_2$, (f) $-OCF_3$, (g) $-OCF_2H$, (h) $-OCFH_2$, (i) $-OCH_3$, (j) $-OR^{11}$, (k) $-C(O)R^{11}$, (l) $-C(O)NR^{11}R^{11}$, (m)

$-NH_2$, (n) $-NR^{11}R^{11}$, (o) $-NR^{11}C(O)R^{11}$, (p) $-S(O)_pR^{11}$, (q) $-C(O)OH$, (r) $-C(O)OR^{11}$, (s) $-C_1-C_8$ alkyl, (t) $-C_2-C_8$ alkenyl, (u) $-C_2-C_8$ alkynyl, (v) haloalkyl, (w) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (x) –3–14 membered saturated, unsaturated, or aromatic carbocycle;

wherein each (s) through (x) is optionally substituted with one or more R^{12};

alternatively, one or more pairs of substituents selected from R^{3a} and R^{3b}, R^{3c} and R^{3d}, R^{3e} and R^{3f}, R^{3g} and R^{3h}, R^{3i} and R^{3j}, and R^{3k} and R^{3l} are taken together with the carbon atom to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic, (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (c) an exo carbon-carbon double bond, (d) carbonyl group, or (e) thiocarbonyl group;

wherein each (a) through (b) is optionally substituted with one or more R^{12};

alternatively, wherein two substituents selected from R^{3a}, R^{3b}, R^{3c}, R^{3d}, R^{3e}, R^{3f}, R^{3g}, R^{3h}, R^{3i}, R^{3j}, R^{3k}, and R^{3l} on different carbon atoms are taken together with the intervening atoms to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur;

wherein each (a) through (b) is optionally substituted with one or more R^{12};

alternatively, wherein two substituents selected from R^{3a}, R^{3b}, R^{3c}, R^{3d}, R^{3e}, R^{3f}, R^{3g}, R^{3h}, R^{3i}, R^{3j}, R^{3k}, and R^{3l} on two adjacent carbon atoms are taken together with the bond between said adjacent carbon atoms form a substituted or unsubstituted carbon-carbon double bond, or wherein four substituents selected from R^{3a}, R^{3b}, R^{3c}, R^{3d}, R^{3e}, R^{3f}, R^{3g}, R^{3h}, R^{3i}, R^{3j}, R^{3k}, and R^{3l} on two adjacent carbon atoms are taken together with the bond between said adjacent carbon atoms form a carbon-carbon triple bond;

U is selected from –O–, $-S(O)_p-$, $-NR^{11}-$, –(C=O)–, $-NR^{11}(C=O)-$, $-(C=O)NR^{11}-$, $-S(O)_pNR^{11}-$, $-NR^{11}S(O)_p-$, $-NR^{11}S(O)_pNR^{11}-$, and $-NR^{11}C(O)NR^{11}-$;


T is selected from $-NR^{11}R^{11}$, $-NR^{11}(C=O)OR^{11}$, $-NR^{11}(C=NR^{11})NR^{11}R^{11}$, and OR^{11};

alternatively, one R^{11} and one substituent selected from R^{3a}, R^{3b}, R^{3c}, R^{3d}, R^{3e}, R^{3f}, R^{3g}, R^{3h}, R^{3i}, R^{3j}, R^{3k}, and R^{3l} are taken together with the intervening atoms to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7

membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur;

wherein each (a) through (b) is optionally substituted with one or more R^{12};

R^9 is selected from:



, and ;

wherein R^{9k}, R^{9l}, R^{9m}, R^{9n}, R^{9o}, R^{9p}, R^{9q}, R^{9r}, R^{9s}, and R^{9t} are each independently selected from (a) hydrogen, (b) halogen, (c) $-CN$, (d) $-N_3$, (e) $-NO_2$, (f) $-OCF_3$, (g) $-OCH_3$, (h) $-OCF_2H$, (i) $-OCFH_2$, (j) $-OR^{11}$, (k) $-NH_2$, (l) $-NR^{11}R^{11}$, (m) $-C(O)R^{11}$, (n) $-C(O)OR^{11}$, (o) $-C(O)NR^{11}R^{11}$, (p) $-NR^{11}C(O)R^{11}$, (q) $-S(O)_pR^{11}$, (r) $-C_1-C_8$ alkyl, (s) $-C_2-C_8$ alkenyl, (t) $-C_1-C_8$ alkynyl, (u) haloalkyl, (v) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (w) –3–14 membered saturated, unsaturated, or aromatic carbocycle;

wherein each (r) through (w) is optionally substituted with one or more R^{12};

alternatively, one or more pairs of substituents selected from R^{9k} and R^{9l}, R^{9m} and R^{9n}, R^{9o} and R^{9p}, R^{9q} and R^{9r}, and R^{9s} and R^{9t} are taken together with the carbon atom to which they are attached to form (a) 3–7 membered saturated or unsaturated carbocyclic, (b) 3–7

membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (c) an exo carbon-carbon double bond, (d) carbonyl group, or (e) thiocarbonyl group;

wherein each (a) through (c) is optionally substituted with one or more R^{12};

alternatively, two substituents selected from R^{9k}, R^{9l}, R^{9m}, R^{9n}, R^{9o}, R^{9p}, R^{9q}, R^{9r}, R^{9s}, and R^{9t} on different carbon atoms are taken together with the intervening atoms to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur;

wherein each (a) through (b) is optionally substituted with one or more R^{12};

alternatively, two substituents selected from R^{9k}, R^{9l}, R^{9m}, R^{9n}, R^{9o}, R^{9p}, R^{9q}, R^{9r}, R^{9s}, and R^{9t} on two adjacent carbon atoms are taken together with the bond between said adjacent carbon atoms form a substituted or unsubstituted carbon-carbon double bond, or four substituents selected from R^{9k}, R^{9l}, R^{9m}, R^{9n}, R^{9o}, R^{9p}, R^{9q}, R^{9r}, R^{9s}, and R^{9t} on two adjacent carbon atoms are taken together with the bond between said adjacent carbon atoms form a carbon-carbon triple bond;

Z is selected from –O–, $-S(O)_p-$, $-NR^{11}-$, –(C=O)–, $-NR^{11}(C=O)-$, $-(C=O)NR^{11}-$, $-S(O)_pNR^{11}-$, $-NR^{11}S(O)_p-$, $-NR^{11}S(O)_pNR^{11}-$, and $-NR^{11}C(O)NR^{11}-$;

W is selected from $-NR^{11}R^{11}$, $-NR^{11}(CO)OR^{11}$, $-NR^{11}(C=NR^{11})NR^{11}R^{11}$, and $-OR^{11}$;

alternatively, one R^{11} and one substituent selected from R^{9k}, R^{9l}, R^{9m}, R^{9n}, R^{9o}, R^{9p}, R^{9q}, R^{9r}, R^{9s}, and R^{9t} are taken together with the intervening atoms to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur;

wherein each (a) through (b) is optionally substituted with one or more R^{12};

R^{12} is independently selected from (a) hydrogen, (b) halogen, (c) –OH, (d) –SH, (e) –(C_1–C_8 alkyl)OH, (f) $-OCF_3$, (g) $-OCH_3$, (h) $-OCF_2H$, (i) $-OCFH_2$, (j) –O(C_1–C_8 alkyl), (k) –CN, (l) $-NO_2$, (m) $-CONH_2$, (n) C(O)NH(C_1-C_8 alkyl), (o) C(O)N(C_1-C_8 alkyl)$_2$, (p) –COH, (q) $-COCH_3$, (r) $-S(O)_pCH_3$, (s) $-S(O)_pN(C_1$–C_8 alkyl)$_2$, (t) –S(C_1–C_8 alkyl), (u) –C(O)OH, (v) –C(O)O(C_1–C_8 alkyl), (w) $-N_3$, (x) –NHC(O)(C_1–C_8 alkyl), (y) –N(C_1–C_8 alkyl)C(O)(C_1–C_8 alkyl), (z) $-NH_2$, (aa) –NH(C_1–C_8 alkyl), (bb) –N(C_1–C_8 alkyl)$_2$, (cc) –C_1–C_8 alkyl, (dd) –C_2–C_8 alkenyl, (ee) –C_2–C_8 alkynyl, (ff) –haloalkyl, (gg) –(C_1–C_8 alkyl)–(3–14 membered

saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (hh) –(C_1–C_8 alkyl)–(3–14 membered saturated, unsaturated, or aromatic carbocycle), (ii) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (jj) –3–14 membered saturated, unsaturated, or aromatic carbocycle, (kk) –(C=NH)NH_2, (ll) –C(=NH)NH_2, (mm) –C(O)R^{13}, (nn) =O, and (oo) =NR^{13};


wherein each (aa) through (jj) is optionally substituted with one or more R^{13};

R^{13} is independently selected from (a) hydrogen, (b) halogen, (c) –C_1–C_8 alkyl, (d) –C_2–C_8 alkenyl, (e) –C_2–C_8 alkynyl, (f) –haloalkyl, (g) –OH, (h) –OC_1-C_8 alkyl, (i) –OC_2–C_8 alkenyl, (j) –OC_2–C_8 alkynyl, (k) –OCF_3, (l) –OCH_3, (m) –OCF_2H, (n) –$OCFH_2$, (o) –NH_2, (p) –CN, (q) –N_3, (r) –$S(O)_pC_1$-C_8 alkyl, (s) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (t) –3–14 membered saturated, unsaturated, or aromatic carbocycle;

p is 0, 1, or 2; and

t is 0, 1, or 2.

2. The compound according to claim 1 having the formula:



(I),

or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, wherein

X_1 is CR^1 or N; X_2 is CR^2 or N; X_3 is CR^3 or N; X_4 is CR^4 or N; X_5 is CR^5 or N; with the proviso that X_1, X_2, X_3, X_4, and X_5 are not all N;

Y_6 is CR^6 or N; Y_7 is CR^7 or N; Y_8 is CR^8 or N; Y_9 is CR^9 or N; Y_{10} is CR^{10} or N; with the proviso that Y_6, Y_7, Y_8, Y_9, and Y_{10} are not all N; wherein

R^1, R^2, R^4, R^5, R^6, R^7, R^8 and R^{10} are each independently selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) –CF_3, (g) –CF_2H, (h) –CFH_2, (i) –OCF_3, (j) –OCF_2H, (k) –

$OCFH_2$, (l) $-OCH_3$, (m) –CN, (n) $-N_3$, (o) $-NO_2$, (p) $-NR^{11}R^{11}$, (q) $-NR^{11}(CO)R^{11}$, (r) $-(CO)NR^{11}R^{11}$, (s) $-OR^{11}$, (t) –COH, (u) $-CO(C_1-C_8$ alkyl), (v) $-COR^{11}$, (w) $-NR^{11}(CNR^{11})NR^{11}R^{11}$, (x) $-S(O)_pR^{11}$, (y) $-NR^{11}S(O)_pR^{11}$, (z) $-SR^{11}$, (aa) $-SCF_3$, (bb) $-C(CF_3)H$-NH-$CHR^{11}R^{11}$, (cc) $-COOR^{11}$, (dd) $-(OCH_2CH_2)_tR^{11}$, (ee) $-(OCH_2CH_2)_tOR^{11}$, (ff) $-C_1-C_8$ alkyl, (gg) $-C_2-C_8$ alkenyl, (hh) $-C_2-C_8$ alkynyl, (ii) $-(C_1-C_8$ alkyl)–(3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (jj) $-(C_1-C_8$ alkyl)–(3–14 membered saturated, unsaturated, or aromatic carbocycle), (kk) –haloalkyl, (ll) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (mm) –3–14 membered saturated, unsaturated, or aromatic carbocycle, and (nn) $-CHR^{11}$-NH-(3-14 membered saturated, unsaturated, or aromatic heterocycle containing one of more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur);

wherein each (ff) through (nn) is optionally substituted with one or more R^{12};


each R^{11} is independently selected from (a) hydrogen, (b) halogen, (c) $-CF_3$, (d) $-CF_2H$, (e) $-CFH_2$, (f) –OH, (g) –SH, (h) $-(C_1-C_8$ alkyl)OH, (i) $-OCF_3$, (j) $-OCF_2H$, (k) $-OCFH_2$, (l) $-OCH_3$, (m) $-OR^{12}$, (n) $-COR^{12}$, (o) –CN, (p) $-NO_2$, (q) $-CONH_2$, (r) $-CONR^{12}R^{12}$, (s) $-C(O)CH_3$, (t) $-S(O)_pCH_3$, (u) $-S(O)_pNR^{12}R^{12}$, (v) $-SR^{12}$, (w) –C(O)OH, (x) $-C(O)OR^{12}$, (y) $-N_3$, (z) $-NH_2$, (aa) $-NR^{12}C(O)R^{12}$, (bb) $-NH(C_1-C_8$ alkyl), (cc) $-N(C_1-C_8$ alkyl)$_2$, (dd) $-C_1-C_8$ alkyl, (ee) $-C_2-C_8$ alkenyl, (ff) $-C_2-C_8$ alkynyl, (gg) –haloalkyl, (hh) $-(C_1-C_8$ alkyl)–(3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (ii) $-(C_1-C_8$ alkyl)–(3–14 membered saturated, unsaturated, or aromatic carbocycle), (jj) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (kk) –3–14 membered saturated, unsaturated, or aromatic carbocycle, and (ll) $-(C=NH)NR^{12}R^{12}$;

wherein each (bb) through (kk) is optionally substituted with one or more R^{12};

alternatively two R^{11} subsituents are taken together to form (a) 3–7 membered saturated or unsaturated carbocyclic or (b) 3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of

nitrogen, oxygen, and sulfur, wherein each (a) through (b) is optionally substituted with one or more R^{12};

R^3 is selected from:



, and ;

wherein R^{3a}, R^{3b}, R^{3c}, R^{3d}, R^{3e}, R^{3f}, R^{3g}, R^{3h}, R^{3i}, and R^{3j} are each independently selected from (a) hydrogen, (b) halogen, (c) $-CH_3$, (d) $-CF_3$, (e) $-CF_2H$, (f) $-CFH_2$, (g) $-OCF_3$, (h) $-OCF_2H$, (i) $-OCFH_2$, (j) $-OCH_3$, (k) $-OR^{11}$, (l) $-C_1-C_8$ alkyl, (m) haloalkyl, (n) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (o) –3–14 membered saturated, unsaturated, or aromatic carbocycle;

wherein each (l) through (o) is optionally substituted with one or more R^{12};

alternatively, one or more pairs of substituents selected from R^{3a} and R^{3b}, R^{3c} and R^{3d}, R^{3e} and R^{3f}, R^{3g} and R^{3h}, and R^{3i} and R^{3j} are taken together with the carbon atom to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic, (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (c) an exo carbon-carbon double bond, (d) carbonyl group, or (e) thiocarbonyl group;

wherein each (a) through (b) is optionally substituted with one or more R^{12};

alternatively, wherein two substituents selected from R^{3a}, R^{3b}, R^{3c}, R^{3d}, R^{3e}, R^{3f}, R^{3g}, R^{3h}, R^{3i}, and R^{3j} on different carbon atoms are taken together with the intervening atoms to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur;

wherein each (a) through (b) is optionally substituted with one or more R^{12};

alternatively, wherein two substituents selected from R^{3a}, R^{3b}, R^{3c}, R^{3d}, R^{3e}, R^{3f}, R^{3g}, R^{3h}, R^{3i}, and R^{3j} on two adjacent carbon atoms are taken together with the bond between said

adjacent carbon atoms form a substituted or unsubstituted carbon-carbon double bond, or wherein four substituents selected from R^{3a}, R^{3b}, R^{3c}, R^{3d}, R^{3e}, R^{3f}, R^{3g}, R^{3h}, R^{3i}, and R^{3j} on two adjacent carbon atoms are taken together with the bond between said adjacent carbon atoms form a carbon-carbon triple bond;


U is selected from –O–, $-S(O)_p-$, $-NR^{11}-$, –(C=O)–, $-NR^{11}(C=O)-$, $-(C=O)NR^{11}-$, $-S(O)_pNR^{11}-$, $-NR^{11}S(O)_p-$ and $-NR^{11}S(O)_pNR^{11}-$;


T is selected from $-NR^{11}R^{11}$, $-NR^{11}(C=O)OR^{11}$, $-NR^{11}(C=NR^{11})NR^{11}R^{11}$, and OR^{11};


alternatively, one R^{11} and one substituent selected from R^{3a}, R^{3b}, R^{3c}, R^{3d}, R^{3e}, R^{3f}, R^{3g}, R^{3h}, R^{3i}, and R^{3j} are taken together with the intervening atoms to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur;

wherein each (a) through (b) is optionally substituted with one or more R^{12};

R^9 is selected from:


,


,


, and ;

wherein R^{9k}, R^{9l}, R^{9m}, R^{9n}, R^{9o}, R^{9p}, R^{9q}, R^{9r}, R^{9s}, and R^{9t} are each independently selected from (a) hydrogen, (b) halogen, (c) $-CH_3$, (d) $-CF_3$, (e) $-CF_2H$, (f) $-CFH_2$, (g) –

OCF_3, (h) $-OCH_3$, (i) $-OCF_2H$, (j) $-OCFH_2$, (k) $-OR^{11}$, (l) $-C_1-C_8$ alkyl, (m) haloalkyl, (n) – 3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (o) –3–14 membered saturated, unsaturated, or aromatic carbocycle;

wherein each (l) through (o) is optionally substituted with one or more R^{12};

alternatively, one or more pairs of substituents selected from R^{9k} and R^{9l}, R^{9m} and R^{9n}, R^{9o} and R^{9p}, R^{9q} and R^{9r}, and R^{9s} and R^{9t} are taken together with the carbon atom to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic, (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (c) an exo carbon-carbon double bond, (d) carbonyl group, and (e) thiocarbonyl group;

wherein each (a) through (c) is optionally substituted with one or more R^{12};

alternatively, two substituents selected from R^{9k}, R^{9l}, R^{9m}, R^{9n}, R^{9o}, R^{9p}, R^{9q}, R^{9r}, R^{9s}, and R^{9t} on different carbon atoms are taken together with the intervening atoms to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur;

wherein each (a) through (b) is optionally substituted with one or more R^{12};

alternatively, two substituents selected from R^{9k}, R^{9l}, R^{9m}, R^{9n}, R^{9o}, R^{9p}, R^{9q}, R^{9r}, R^{9s}, and R^{9t} on two adjacent carbon atoms are taken together with the bond between said adjacent carbon atoms form a substituted or unsubstituted carbon-carbon double bond, or four substituents selected from R^{9k}, R^{9l}, R^{9m}, R^{9n}, R^{9o}, R^{9p}, R^{9q}, R^{9r}, R^{9s}, and R^{9t} on two adjacent carbon atoms are taken together with the bond between said adjacent carbon atoms form a carbon-carbon triple bond;

Z is selected from –O–, $-S(O)_p-$, $-NR^{11}-$, –(C=O)–, $-NR^{11}(C=O)-$, $-(C=O)NR^{11}-$, $-S(O)_pNR^{11}-$, $-NR^{11}S(O)_p-$ and $-NR^{11}S(O)_pNR^{11}-$;

W is selected from $-NR^{11}R^{11}$, $-NR^{11}(CO)OR^{11}$, $-NR^{11}(C=NR^{11})NR^{11}R^{11}$, and $-OR^{11}$;

alternatively, one R^{11} and one substituent selected from R^{9k}, R^{9l}, R^{9m}, R^{9n}, R^{9o}, R^{9p}, R^{9q}, R^{9r}, R^{9s}, and R^{9t} are taken together with the intervening atoms to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur;


wherein each (a) through (b) is optionally substituted with one or more R^{12};

R^{12} is independently selected from (a) hydrogen, (b) halogen, (c) $-CF_3$, (d) $-CF_2H$, (e) $-CFH_2$, (f) –OH, (g) –SH, (h) $-(C_1-C_8$ alkyl)OH, (i) $-OCF_3$, (j) $-OCH_3$, (k) $-OCF_2H$, (l) $-OCFH_2$, (m) $-O(C_1-C_8$ alkyl), (n) –CN, (o) $-NO_2$, (p) $-CONH_2$, (q) –C(O)H, (r) $-C(O)CH_3$, (s) $-S(O)_pCH_3$, (t) $-S(O)_pN(C_1-C_8$ alkyl)$_2$, (u) $-S(C_1-C_8$ alkyl), (v) –C(O)OH, (w) $-C(O)O(C_1-C_8$ alkyl), (x) $-N_3$, (y) $-NHC(O)(C_1-C_8$ alkyl), (z) $-N(C_1-C_8$ alkyl)$C(O)(C_1-C_8$ alkyl), (aa) $-NH_2$, (bb) $-NH(C_1-C_8$ alkyl), (cc) $-N(C_1-C_8$ alkyl)$_2$, (dd) $-C_1-C_8$ alkyl, (ee) $-C_2-C_8$ alkenyl, (ff) $-C_2-C_8$ alkynyl, (gg) –haloalkyl, (hh) $-(C_1-C_8$ alkyl)–(3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (ii) $-(C_1-C_8$ alkyl)–(3–14 membered saturated, unsaturated, or aromatic carbocycle), (jj) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (kk) –3–14 membered saturated, unsaturated, or aromatic carbocycle, (ll) $-(C=NH)NH_2$, (mm) $-C(O)NH(C_1$-C_8 alkyl), (nn) $-C(O)N(C_1$-C_8 alkyl)$_2$, and (oo) $-C(=NH)NH_2$;

p is 0, 1, or 2; and

t is 0, 1, or 2.


3. The compound according to claim 2 having the formula:



(II),

or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.


4. The compound according to claim 3 having the formula:



(III),

or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.


5. The compound according to claim 4 having the formula:




(IV),

or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.


6. The compound according to claim 5 having a formula selected from:




(V),




(VI),




(VII),




(VIII),




(IX),




(X),



(XI),




(XXa), and




(XXa1)

or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.


7. The compound according to claim 6 having a formula selected from:




(Va),




(VIa),




(VIIa),




(VIIIa),



(IXa),




(Xa), and




(XIa)

or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.


8. The compound according to claim 5 having a formula selected from:




(XII),




(XIII),




(XIV),




(XV),




(XVI),




(XVII),



(XVIII),




(XXb), and




(XXb1)

or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.


9. The compound according to claim 8 having a formula selected from:




(XIIa),




(XIIIa),




(XIVa),




(XVa),



(XVIa),



(XVIIa),



and (XVIIIa)

or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.

10. The compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, according to any one of claims 1-9, wherein at least one substituent selected from R^{9k}, R^{9l}, R^{9m}, R^{9n}, R^{9o}, R^{9p}, R^{9q}, R^{9r}, R^{9s}, and R^{9t} is not hydrogen.

11. The compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, according to any one of claims 1-9, wherein at least two substituents selected from R^{9k}, R^{9l}, R^{9m}, R^{9n}, R^{9o}, R^{9p}, R^{9q}, R^{9r}, R^{9s}, and R^{9t} are not hydrogen.


12. The compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, according to any one of claims 1-11, wherein R^1, R^2, R^4 and R^5 are each independently selected from hydrogen and F.


13. The compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, according to claim 12 wherein R^1, R^2, R^4, and R^5 are each hydrogen.


14. The compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, according to any one of claims 1-13, wherein R^{3a} and R^{3b} are each independently selected from (a) hydrogen, (b) F, (c) Cl, (d) $-CH_3$, (e) $-CF_3$, (f) $-CF_2H$, (g) $-CFH_2$, (h) $-OCF_3$, (i) $-OCF_2H$, (j) $-OCFH_2$, (k) $-OCH_3$, and (l) $-OH$.


15. The compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, according to claim 14, wherein R^{3a} and R^{3b} are each hydrogen.

16. The compound according to claim 8 having a formula selected from:



(A1),


(A2),



(A3),




(A4),



(A5),




(A6), and




(A7);

or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.


17. The compound according to claim 8 having a formula selected from:




(B1),




(B2),




(B3),




(B4),



(B5),




(B6), and




(B7),

or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.


18. The compound according to claim 8 having a formula selected from:




(C1),




(C2),





(C3),



(C4),



(C5),


(C6), and



(C7);

or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.


19. The compound according to claim 8 having a formula selected from:




(D1),




(D2),





(D3),



(D4),



(D5),


(D6), and



(D7);

or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.


20. The compound according to claim 8 having a formula selected from:




(E1),




(E2),




(E3),




(E4),



(E5)




(E6), and




(E7);

or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.


21. The compound according to claim 16 having a formula selected from:




(A1a),




(A2a),




(A3a),




(A4a),




(A5a),




(A6a),



(A7a),




(A8a), and




(A9a)

or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.


22. The compound according to claim 17 having a formula selected from:




(B1a),




(B2a),




(B3a),




(B4a),




(B5a),




(B6a),



(B7a),




(B8a), and




(B9a)

or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.


23. The compound according to claim 18 having a formula selected from:




(C1a),




(C2a),





(C3a),





(C4a),


(C5a),


(C6a),


(C7a),



(C8a), and




(C9a)

or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.


24. The compound according to claim 19 having a formula selected from:




(D1a),




(D2a),




(D3a),




(D4a),




(D5a),




(D6a),



(D7a),




(D8a), and




(D9a)

or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.


25. The compound according to claim 20 having a formula selected from:




(E1a),




(E2a),




(E3a),




(E4a),




(E5a)



(E6a),



(E7a), and



(E8a)

or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.

26. The compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, according to any one of claims 1-25, wherein R^{10} is selected from hydrogen, F and Cl.

27. The compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, according to any one of claims 1-26, wherein R^6, R^7, and R^8 are each independently selected from (a) F, (b) Cl, (c) $-CF_3$, (d) $-CF_2H$, (e) $-CFH_2$, (f) $-OCF_3$, (g) $-OCF_2H$, (h) $-OCFH_2$, (i) $-OCH_3$, (j) $-CN$, (k) $-OR^{11}$, (l) $-S(O)_pR^{11}$, (m) $-SCF_3$, (n) $-C_1-C_8$ alkyl, (o) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (p) –3–14 membered saturated, unsaturated, or aromatic carbocycle, (q) –CHCHCN and (r) –CHCH-C(O)NH-t-butyl.

28. The compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, according to claim 27, wherein R^6, R^7, and R^8 are each independently selected from (a) F, (b) Cl, (c) $-CF_3$, (d) $-CF_2H$, (e) $-CFH_2$, (f) $-OCF_3$, (g) $-OCF_2H$, (h) $-OCFH_2$, (i) $-OCH_3$, (j) $-CN$, (k) $-OR^{11}$, (l) $-S(O)_pR^{11}$, (m) $-SCF_3$, (n) $-C_1-C_8$ alkyl, (o) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (p) –3–14 membered saturated, unsaturated, or aromatic carbocycle.

29. The compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, according to claim 28, wherein R^6, R^7, and R^8 are each independently selected from are each independently selected from (a) F; (b) Cl; (c) $-CF_3$; (d) $-CF_2H$; (e) $-CFH_2$; (f) $-OCF_3$; (g) $-OCF_2H$; (h) $-OCFH_2$; (i) $-OCH_3$; (j) $-O(C_1-C_4$ alkyl); (k) $-S(O)CH_3$; (l) $-S(O)CF_3$; (m) $-S(O)_2CH_3$; (n) $-S(O)_2CF_3$; (o) $-SCF_3$;

(p) $-C_1-C_4$ alkyl selected from methyl, ethyl, isopropyl, and t-butyl;

(q) –3–7 membered saturated, unsaturated, or aromatic heterocycle selected from oxetanyl, azepanyl, pyridyl, dihydropyridyl, furanyl, tetrahydrofuranyl, tetrahydropyridyl, azetidinyl, pyrrolidinyl, piperidinyl, and piperidenyl; and

(r) –3–7 membered saturated, unsaturated, or aromatic carbocycle selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, cyclohexenyl, and cyclohexadienyl.

30. The compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, according to claim 29, wherein R^6, R^7, and R^8 are each independently selected from are each independently selected from (a) F, (b) Cl, (c) $-CF_3$, (d) $-OCF_3$, (e) $-OCH_3$, (f) methyl, (g) ethyl, (h) isopropyl, (i) t-butyl, (j) azepanyl, (k) cyclopropyl, (l) cyclobutyl, (m) cyclohexyl, (n) phenyl, (o) pyridyl, (p) azetidinyl, (q) pyrrolidinyl, (r) piperidinyl, and (s) piperidenyl.

31. The compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, according to any one of claims 1-19, 21-24, and 26-30, wherein R^{9k}, R^{9l}, R^{9m}, R^{9n}, R^{9o}, R^{9p}, R^{9q}, R^{9r}, R^{9s}, and R^{9t} are each independently selected from (a) hydrogen, (b) halogen, (c) $-CF_3$, (d) $-CF_2H$, (e) $-CFH_2$, (f) $-OCF_3$, (g) $-OCH_3$, (h) $-OCF_2H$, (i) $-OCFH_2$, (j) $-OR^{11}$, (k) $-C_1-C_8$ alkyl, (l) haloalkyl, (m) –3–14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (n) –3–14 membered saturated, unsaturated, or aromatic carbocycle;

alternatively, one or more of pairs of substituents selected from R^{9k} and R^{9l}, R^{9m} and R^{9n}, R^{9o} and R^{9p}, R^{9q} and R^{9r}, and R^{9s} and R^{9t} are taken together with the carbon atom to which they are attached to form (a) –3–7 membered saturated or unsaturated carbocyclic or (b) –3–7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; and

at least one substituent selected from R^{9k}, R^{9l}, R^{9m}, R^{9n}, R^{9o}, R^{9p}, R^{9q}, R^{9r}, R^{9s}, and R^{9t} is not hydrogen.

32. The compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, according to claim 31, wherein R^{9k}, R^{9l}, R^{9m}, R^{9n}, R^{9o}, R^{9p}, R^{9q}, R^{9r}, R^{9s}, and R^{9t} are each independently selected from (a) hydrogen; (b) halogen; (c) $-CF_3$; (d) $-CF_2H$; (e) $-CFH_2$; (f) $-OCF_3$; (g) $-OCH_3$; (h) $-OCF_2H$; (i) $-OCFH_2$; (j) $-OH$; (k) $-O(C_1-C_4$ alkyl);

(l) $-C_1-C_4$ alkyl selected from methyl, ethyl, isopropyl, and t-butyl;

(m) –3–7 membered saturated, unsaturated, or aromatic heterocycle selected from oxetanyl, azepanyl, pyridyl, dihydropyridyl, furanyl, tetrahydrofuranyl, tetrahydropyridyl, azetidinyl, pyrrolidinyl, piperidinyl, and piperidenyl; and

(n) –3–7 membered saturated, unsaturated, or aromatic carbocycle selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, cyclohexenyl, and cyclohexadienyl;


alternatively, one or more of pairs of substituents are selected from R^{9k} and R^{9l}, R^{9m} and R^{9n}, R^{9o} and R^{9p}, R^{9q} and R^{9r}, and R^{9s} and R^{9t} are taken together with the carbon atom to which they are attached form cyclopropyl, cyclobutyl, or oxetanyl; and

at least one substituent selected from R^{9k}, R^{9l}, R^{9m}, R^{9n}, R^{9o}, R^{9p}, R^{9q}, R^{9r}, R^{9s}, and R^{9t} is not hydrogen;

33. The compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, according to claim 32 wherein R^{9k}, R^{9l}, R^{9m}, R^{9n}, R^{9o}, R^{9p}, R^{9q}, R^{9r}, R^{9s}, and R^{9t} are each independently selected from (a) hydrogen, (b) halogen, (d) $-CF_3$, (e) $-CF_2H$, (f) $-CFH_2$, (g) $-OCF_3$, (h) $-OCH_3$, (i) $-OCF_2H$, (j) $-OCFH_2$, (k) –OH, (l) $-OCH_3$, (l) methyl, (m) ethyl, (n) isopropyl, and (o) t-butyl; and

at least one substituent selected from R^{9k}, R^{9l}, R^{9m}, R^{9n}, R^{9o}, R^{9p}, R^{9q}, R^{9r}, R^{9s}, and R^{9t} is not hydrogen.


34. The compound according to any one of claims 1-5 having the formula:



(F1),

or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.

35. The compound according to any one of claims 1-5 having the formula:



(F2),

or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.

36. The compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, according to any one of claims 34-35, wherein

Z is selected from –O–, $-S(O)_p-$, $-NR^{11}-$, –(C=O)–, $-NR^{11}(C=O)-$, $-(C=O)NR^{11}-$, $-S(O)_pNR^{11}-$, $-NR^{11}S(O)_p-$, and $-NR^{11}S(O)_pNR^{11}-$;

R^{3a} is selected from halogen and C_1–C_6 alkyl;

R^{3b} is selected from hydrogen, halogen, $-OCF_3$, $-OCF_2H$, $-OCFH_2$, $-OCH_3$, $-OR^{11}$, C_1–C_6 alkyl, and haloalkyl;

R^6, R^7, and R^8 are each independently selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) $-CF_3$, (g) $-CF_2H$, (h) $-CFH_2$, (i) $-OCF_3$, (j) $-OCF_2H$, (k) $-OCFH_2$, (l) $-OCH_3$, (m) –CN, (n) $-N_3$, (o) $-NO_2$, (p) $-NR^{11}R^{11}$, (q) $-NR^{11}(CO)R^{11}$, (r) $-(CO)NR^{11}R^{11}$, (s) $-OR^{11}$, (t) –COH, (u) $-CO(C_1-C_8$ alkyl), (v) $-COR^{11}$, (w) $-NR^{11}(CNR^{11})NR^{11}R^{11}$, (x) $-S(O)_pR^{11}$, (y) $-NR^{11}S(O)_pR^{11}$, (z) $-SR^{11}$, (aa) $-SCF_3$, (bb) $-C(CF_3)H$-NH-$CHR^{11}R^{11}$, (cc) $-COOR^{11}$, (dd) $-(OCH_2CH_2)_tR^{11}$, (ee) $-(OCH_2CH_2)_tOR^{11}$, (ff) $-C_1-C_8$ alkyl, (gg) $-C_2-C_8$ alkenyl, and (hh) $-C_2-C_8$ alkynyl;

R^{9o}, R^{9p}, R^{9q}, and R^{9r} are each independently selected from (a) hydrogen, (b) halogen, (c) $-OCF_3$, (d) $-OCH_3$, (e) $-OCF_2H$, (f) $-OCFH_2$, (g) $-OR^{11}$, (h) $-C_1-C_8$ alkyl, and (i) haloalkyl;

R^{11} is selected from hydrogen, $-C_1-C_6$ alkyl, $-C_2-C_6$ alkenyl, $-C_2-C_6$ alkynyl, and haloalkyl;

p is 0, 1, or 2; and

t is 0, 1, or 2.

37. The compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, according to claim 34, wherein Z is O;

R^{9o}, R^{9p}, R^{9q}, and R^{9r} are each independently selected from C_1-C_6 alkyl and hydrogen;

R^6 and R^8 are each independently selected from hydrogen, F, Cl, Br, I, –C_1-C_6 alkyl, –CH_2F, –CHF_2, and –CF_3;

R^7 is selected from hydrogen, F, Cl, Br, I, –C_1-C_6 alkyl, –CH_2F, –CHF_2, –CF_3, –OC_1-C_6 alkyl, –$S(O)_p$-C_1-C_6 alkyl, –OCH_2F, –$OCHF_2$, –OCF_3, –$S(O)_p$-CH_3, –$S(O)_p$-CH_2F, and –$S(O)_p$-CF_3; and

R^{3a} is selected from halogen and –C_1–C_6 alkyl;

R^{3b} is selected from hydrogen, halogen, –CF_3, –CF_2H, –CFH_2, –C_1–C_6 alkyl, and haloalkyl; and

p is 0, 1, or 2.

38. The compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, according to claim 35, wherein R^{9o}, R^{9p}, R^{9q}, and R^{9r} are each independently selected from –C_1-C_6 alkyl and hydrogen;

R^6 and R^8 are each independently selected from hydrogen, F, Cl, Br, I, –C_1-C_6 alkyl, –CH_2F, –CHF_2, and –CF_3;


R^7 is selected from hydrogen, F, Cl, Br, I, –C_1-C_6 alkyl, –CH_2F, –CHF_2, –CF_3, –OC_1-C_6 alkyl, –$S(O)_p$-C_1-C_6 alkyl, –OCH_2F, O–CHF_2, –OCF_3, –$S(O)_p$-CH_3, –$S(O)_p$-CH_2F, and –$S(O)_p$-CF_3; and

R^{3a} is selected from halogen and –C_1–C_6 alkyl;


R^{3b} is selected from hydrogen, halogen, –CF_3, –CF_2H, –CFH_2, –C_1–C_6 alkyl, and haloalkyl; and

p is 0, 1, or 2.


39. The compound according to any one of claims 1-5 having a formula selected from:




(G1),



(G2),



(G3), and




(G4),

or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.


40. The compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, according to claim 39, wherein R^{9o}, R^{9p}, R^{9q}, and R^{9r} are each independently selected from $-C_1$-C_6 alkyl and hydrogen;
R^6 and R^8 are each independently selected from hydrogen, F, Cl, Br, I, $-C_1$-C_6 alkyl, $-CH_2F$, $-CHF_2$, and $-CF_3$;
R^7 is selected from hydrogen, F, Cl, Br, I, $-C_1$-C_6 alkyl, $-CH_2F$, $-CHF_2$, $-CF_3$, $-OC_1$-C_6 alkyl, $-S(O)_p$-C_1-C_6 alkyl, $-OCH_2F$, $-OCHF_2$, $-OCF_3$, $-S(O)_p$-CH_3, $-S(O)_p$-CH_2F, and $-S(O)_p$-CF_3; and
R^{3a} is selected from halogen and C_1–C_6 alkyl; and
p is 0, 1, or 2.

41. The compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, according to any one of claims 39-40, wherein R^{9o}, R^{9p}, R^{9q}, and R^{9r} are each independently selected from C_1-C_6 alkyl and hydrogen;
R^6 is selected from hydrogen, F, Cl, Br, I, $-C_1$-C_6 alkyl, $-CH_2F$, $-CHF_2$, and $-CF_3$;
R^7 is selected from hydrogen, F, Cl, Br, I, $-C_1$-C_6 alkyl, $-CH_2F$, $-CHF_2$, $-CF_3$, $-OC_1$-C_6 alkyl, $-S(O)_p$-C_1-C_6 alkyl, $-OCH_2F$, $-OCHF_2$, $-OCF_3$, $-S(O)_p$-CH_3, $-S(O)_p$-CH_2F, and $-S(O)_p$-CF_3;
R^8 is hydrogen;
R^{3a} is selected from halogen and $-C_1$–C_6 alkyl; and
p is 0, 1, or 2.


42. The compound according to any one of claims 1-5 having a formula selected from:




(H1),



(H2),




(H3), and




(H4),

or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.


43. The compound according any one of claims 1-5 having a formula selected from:




(H5),




(H6),




(H7),




(H8),




(H9),



(H10),



(H11), and



(H12),

or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.

44. The compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, according to claim 42, wherein R^{9q} and R^{9r} are each independently selected from C_1-C_6 alkyl and hydrogen;

R^6 and R^8 are each independently selected from hydrogen, F, Cl, Br, I, $-C_1$-C_6 alkyl, $-CH_2F$, $-CHF_2$, and $-CF_3$;

R^7 is selected from hydrogen, F, Cl, Br, I, $-C_1$-C_6 alkyl, $-CH_2F$, $-CHF_2$, $-CF_3$, $-OC_1$-C_6 alkyl, $-S(O)_p$-C_1-C_6 alkyl, $-OCH_2F$, $-OCHF_2$, $-OCF_3$, $-S(O)_p$-CH_3, $-S(O)_p$-CH_2F, and $-S(O)_p$-CF_3; and

R^{3a} is selected from halogen and $-C_1-C_6$ alkyl; and

p is 0, 1, or 2.

45. The compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, according to claim 42, wherein R^{9q} and R^{9r} are each independently selected from $-C_1$-C_6 alkyl and hydrogen;

R^6 is selected from hydrogen, F, Cl, Br, I, $-C_1$-C_6 alkyl, $-CH_2F$, $-CHF_2$, and $-CF_3$;

R^7 is selected from hydrogen, F, Cl, Br, I, $-C_1$-C_6 alkyl, $-CH_2F$, $-CHF_2$, $-CF_3$, $-OC_1$-C_6 alkyl, $-S(O)_p$-C_1-C_6 alkyl, $-OCH_2F$, $-OCHF_2$, $-OCF_3$, $-S(O)_p$-CH_3, $-S(O)_p$-CH_2F, and $-S(O)_p$-CF_3;

R^8 is hydrogen;


R^{3a} is selected from halogen and $-C_1-C_6$ alkyl; and

p is 0, 1, or 2.


46. The compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, according to claim 43, wherein R^{9r} is $-C_1$-C_6 alkyl;
R^6 is selected from hydrogen, F, Cl, Br, I, $-C_1$-C_6 alkyl, $-CH_2F$, $-CHF_2$, and $-CF_3$;
R^7 is selected from hydrogen, F, Cl, Br, I, $-C_1$-C_6 alkyl, $-CH_2F$, $-CHF_2$, $-CF_3$, $-OC_1$-C_6 alkyl, $-S(O)_p$-C_1-C_6 alkyl, $-OCH_2F$, $-OCHF_2$, $-OCF_3$, $-S(O)_p$-CH_3, $-S(O)_p$-CH_2F, and $-S(O)_p$-CF_3;
R^8 is hydrogen;
R^{3a} is selected from halogen and $-C_1$–C_6 alkyl; and
p is 0, 1, or 2.

47. The compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, according to claim 43, wherein R^{9r} is $-CH_3$;
R^6 is selected from hydrogen, F, Cl, Br, I, $-C_1$-C_6 alkyl, $-CH_2F$, $-CHF_2$, and $-CF_3$;
R^7 is selected from hydrogen, F, Cl, Br, I, $-C_1$-C_6 alkyl, $-CH_2F$, CHF_2, $-CF_3$, $-OC_1$-C_6 alkyl, $-S(O)_p$-C_1-C_6 alkyl, $-OCH_2F$, $-OCHF_2$, $-OCF_3$, $-S(O)_p$-CH_3, $-S(O)_p$-CH_2F, and $-S(O)_p$-CF_3;
R^8 is hydrogen;
R^{3a} is $-CH_3$; and
p is 0, 1, or 2.


48. The compound according to any one of claims 1-5 having a formula selected from:




(I1),



(I2),




(I3), and




(I4),

or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.


49. The compound according to any one of claims 1-5 having a formula selected from:




(I5),




(I6),




(I7),




(I8),




(I9),



(I10),



(I11), and



(I12),

or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.

50. The compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, according to claim 48, wherein R^{9o} and R^{9p} are each independently selected from $-C_1$-C_6 alkyl and hydrogen;

R^6 and R^8 are each independently selected from hydrogen, F, Cl, Br, I, $-C_1$-C_6 alkyl, $-CH_2F$, $-CHF_2$, and $-CF_3$;

R^7 is selected from hydrogen, F, Cl, Br, I, $-C_1$-C_6 alkyl, $-CH_2F$, $-CHF_2$, $-CF_3$, $-OC_1$-C_6 alkyl, $-S(O)_p$-C_1-C_6 alkyl, $-OCH_2F$, $-OCHF_2$, $-OCF_3$, $-S(O)_p$-CH_3, $-S(O)_p$-CH_2F, and $-S(O)_p$-CF_3; and

R^{3a} is selected from halogen and $-C_1$–C_6 alkyl; and

p is 0, 1, or 2.

51. The compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, according to claim 48, wherein R^{9o} and R^{9p} are each independently selected from C_1-C_6 alkyl and hydrogen;

R^6 is selected from hydrogen, F, Cl, Br, I, $-C_1$-C_6 alkyl, $-CH_2F$, $-CHF_2$, and $-CF_3$;

R^7 is selected from hydrogen, F, Cl, Br, I, $-C_1$-C_6 alkyl, $-CH_2F$, $-CHF_2$, $-CF_3$, $-OC_1$-C_6 alkyl, $-S(O)_p$-C_1-C_6 alkyl, $-OCH_2F$, $OCHF_2$, $-OCF_3$, $S(O)_p$-CH_3, $-S(O)_p$-CH_2F, and $-S(O)_p$-CF_3;

R^8 is hydrogen;

R^{3a} is selected from halogen and $-C_1$–C_6 alkyl; and

p is 0, 1, or 2.

52. The compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, according to claim 49, wherein R^{9o} is $-C_1$-C_6 alkyl;

R^6 is selected from hydrogen, F, Cl, Br, I, $-C_1$-C_6 alkyl, $-CH_2F$, CHF_2, and $-CF_3$;

R^7 is selected from hydrogen, F, Cl, Br, I, $-C_1$-C_6 alkyl, $-CH_2F$, $-CHF_2$, $-CF_3$, $-OC_1$-C_6 alkyl, $-S(O)_p$-C_1-C_6 alkyl, $-OCH_2F$, $-OCHF_2$, $-OCF_3$, $-S(O)_p$-CH_3, $-S(O)_p$-CH_2F, and $-S(O)_p$-CF_3;


R^8 is hydrogen;

R^{3a} is selected from halogen and $-C_1$–C_6 alkyl; and


p is 0, 1, or 2.


53. The compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, according to claim 49, wherein R^{9o} is $-CH_3$;
R^6 is selected from hydrogen, F, Cl, Br, I, $-C_1$-C_6 alkyl, $-CH_2F$, $-CHF_2$, and $-CF_3$;
R^7 is selected from hydrogen, F, Cl, Br, I, $-C_1$-C_6 alkyl, $-CH_2F$, $-CHF_2$, $-CF_3$, $-OC_1$-C_6 alkyl, $-S(O)_p$-C_1-C_6 alkyl, $-OCH_2F$, $-OCHF_2$, $-OCF_3$, $-S(O)_p$-CH_3, $-S(O)_p$-CH_2F, and $-S(O)_p$-CF_3;
R^8 is hydrogen;
R^{3a} is $-CH_3$; and
p is 0, 1, or 2.


54. The compound according to any one of claims 34 (R^{3b} is H), 35 (R^{3b} is H), 39, 42, 43, 48, and 49, wherein the moiety



is selected from:










and .


55. The compound according to any one of claims 34 (R^{3b} is H), 35 (R^{3b} is H), 39, 42, 43, 48, and 49, wherein the moiety



is selected from:







56. A compound according to any of the compounds in Table 1, Table 2, Table 2a and Table 2aa or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.

57. The compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, according to any one of claims 1-56 that binds the ribosome.

58. The compound according to claim 57 or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, wherein the ribosome is a bacterial ribosome.

59. A pharmaceutical composition comprising a compound according to any one of claims 1-56 or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, and a pharmaceutically acceptable carrier.

60. A method of treating, preventing, or reducing the risk of a disease state in a human or animal comprising administering to the human or animal in need thereof an effective amount of a compound according to any one of claims 1-56, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.

61. A method of treating, preventing, or reducing a microbial infection in a human or animal comprising administering to the human or animal an effective amount of a compound according to any one of claims 1-56, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.

62. Use of a compound according to any one of claims 1-56, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, in the manufacture of a medicament for treating, preventing, or reducing a microbial infection in a human or animal.

63. A compound according to any one of claims 1-56, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, for use in treating, preventing, or reducing a microbial infection in a human or animal.

64. A method of treating, preventing, or reducing the risk of a microbial infection in a human or animal comprising administering to the human or animal an effective amount of a compound according to any one of claims 1-56, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, wherein the microbial infection is selected from the group consisting of:

a skin infection, a Gram positive infection, a Gram negative infection, nosocomial pneumonia, community acquired pneumonia, post–viral pneumonia, hospital acquired pneumonia/ventilator associated pneumonia, a respiratory tract infection such as chronic respiratory tract infection (CRTI), acute pelvic infection, a skin infection including an acute bacterial skin and skin structure infection (ABSSSI) and an uncomplicated skin and skin structure infection (uSSSI), a complicated intra-abdominal infection, a urinary tract infection, bacteremia, septicemia, endocarditis, an atrio–ventricular shunt infection, a vascular access infection, meningitis, surgical prophylaxis, a peritoneal infection, a bone infection, a joint infection, a methicillin–resistant *Staphylococcus aureus* infection, a vancomycin–resistant *Enterococci* infection, a linezolid–resistant organism infection, a Bacillus anthracis infection, a Francisella tularensis infection, a Yersinia pestis infection, and tuberculosis.

65. A method according to claim 64, wherein the microbial infection is Gram positive infection.

66. A method according to claim 64, wherein the microbial infection is Gram negative infection.

67. A method of treating, preventing, or reducing the risk of a microbial infection in a human or animal comprising administering to the human or animal an effective amount of a compound according to any one of claims 1-56, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, wherein said infection is caused by or involves one or more microorganisms selected from: *Acinetobacter spp. (Acinetobacter baumanni), Bacteroides distasonis, Bacteroides fragilis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Citrobacter freundii, Citrobacter koser, Clostridium clostridioforme, Clostridium perfringens, Enterobacter aerogenes, Enterobacter cloacae, Enterococcus faecalis, Enterococcus spp., Escherichia coli, Eubacterium lentum, Fusobacterium spp., Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Klebsiella oxytoca, Legionella pneumophilia, Moraxella catarrhalis, Morganella morganii, Mycoplasma spp., Peptostreptococcus spp., Porphyromonas asaccharolytica, Prevotella bivia, Proteus mirabilis, Proteus vulgaris, Providencia rettgeri, Providencia stuartii, Pseudomonas aeruginosa, Serratia marcescens, Streptococcus anginosus, Staphylococcus aureus, Staphylococcus epidermidis, Stenotrophomonas maltophilia, Streptococcus agalactiae, Streptococcus constellatus, Streptococcus pneumoniae, Streptococcus pyogenes,* and *Streptococcus pyogenes.*

68. The method of claim 67, wherein said infection is caused by or involves one or more of aerobic and facultative gram-positive microorganism selected from: *Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus spp., Streptococcus agalactiae, Streptococcus pyogenes*, and *Staphylococcus epidermidis.*

69. The method of claim 67, wherein said infection is caused by or involves one or more of aerobic and facultative gram-negative microorganism selected from: *Escherichia coli,*

Haemophilus influenzae, *Klebsiella pneumoniae*, *Citrobacter freundii*, *Enterobacter aerogenes*, *Enterobacter cloacae*, *Morganella morganii*, *Serratia marcescens*, *Pseudomonas aeruginosa*, *Acinetobacter baumanni*, *Moraxella catarrhalis*, *Proteus mirabilis*, *Citrobacter koseri*, *Haemophilus parainfluenzae*, *Klebsiella oxytoca*, *Proteus vulgaris*, *Providencia rettgeri*, and *Providencia stuartii*.

70. The method of claim 67, wherein said infection is caused by or involves one or more of anaerobic microorganism: *Bacteroides fragilis*, *Bacteroides distasonis*, *Bacteroides ovatus*, *Bacteroides thetaiotaomicron*, *Bacteroides uniformis*, *Clostridium clostridioforme*, *Eubacterium lentum*, *Peptostreptococcus spp.*, *Porphyromonas asaccharolytica*, *Prevotella bivia*, *Bacteroides vulgatus*, *Clostridium perfringens*, and *Fusobacterium spp.*

71. The method according to any of claims 67 and 68, wherein the microorganism *Enterococcus spp.* is selected from vancomycin susceptible isolate and vancomycin resistant isolate.

72. The method according to any of claims 67 and 69, wherein the microorganism *Escherichia coli* is selected from extended spectrum beta-lactamase (ESBL) producing isolate and *Klebsiella pneumoniae* carbapenemase (KPC) producing isolate.

73. The method according to any of claims 67 and 69, wherein the microorganism *Haemophilus influenzae* is a beta-lactamase positive isolate.

74. The method according to any of claims 67 and 69, wherein the microorganism *Klebsiella pneumoniae* is selected from extended spectrum beta-lactamase (ESBL) producing isolate and *Klebsiella pneumoniae* carbapenemase (KPC) producing isolate.

75. The method according to any of claims 67 and 69, wherein the microorganism *Klebsiella oxytoca* selected from extended spectrum beta-lactamase (ESBL) producing isolate and *Klebsiella pneumoniae* carbapenemase (KPC) producing isolate.

76. The method according to any of claims 67 and 68, wherein the microorganism *Staphylococcus aureus* is selected from methicillin susceptible isolate and methicillin resistant isolate.

77. The method according to any of claims 67 and 68, wherein the microorganism *Staphylococcus epidermidis* is selected from methicillin susceptible isolate and methicillin resistant isolate.

78. The method according to any of claims 67 and 68, wherein the microorganism *Streptococcus pneumoniae* is selected from penicillin susceptible isolate and penicillin resistant isolate.

79. The method, use, or compound according to any of claims 60-78 wherein the amount of compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer comprises from 0.1 mg to 1500 mg.

80. The method, use, or compound according to claim 79, wherein the amount of compound or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer comprises about 25 mg, or about 50 mg, or about 75 mg, or about 100 mg, or about 125 mg, or about 150 mg, or about 175 mg, or about 200 mg, or about 225 mg, or about 250 mg, or about 275 mg, or about 300 mg, or about 325, or about 350 mg, or about 375 mg, or about 400 mg, or about 425 mg, or about 450 mg, or about 475 mg, or about 500 mg, or about 525 mg, or about 550 mg, or about 575 mg, or about 600 mg, or about 625 mg, or about 650 mg, or about 675 mg, or about 700 mg, or about 725 mg, or about 750 mg, or about 775 mg, or about 800 mg, or about 825 mg, or about 850 mg, or about 875 mg, or about 900 mg, or about 925 mg, or about 950 mg, or about 975 mg, or about 1000 mg, or about 1025 mg, or about 1050, mg, or about 1075 mg, or about 1100 mg, or about 1125 mg, or about 1150 mg, or about 1175 mg, or about 1200 mg, or about 1225 mg, or about 1250 mg, or about 1275 mg, or about 1300 mg, or about 1325 mg, or about 1350 mg, or about 1375 mg, or about 1400 mg, or about 1425 mg, or about 1450 mg, or about 1475 mg, or about 1500 mg.

81. The method, use, or compound according to any one of claims 60-80 wherein the compound, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer, is administered otically, ophthalmically, nasally, orally, parenterally, topically, or intravenously.

82. A method of synthesizing a compound according to any one of claims 1-56, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.

83. A medical device containing a compound according to any one of claims 1-56, or a tautomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug of said compound or tautomer.

84. The medical device according to claim 83, wherein the device is a stent.

CLAIMS

1. An invention not claimed in any divisional application.